This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

This study has been terminated.
Information provided by:
Nantes University Hospital Identifier:
First received: June 14, 2006
Last updated: June 15, 2006
Last verified: August 2004
The objective of this study is to evaluate the efficacy and safety of Velcade plus dexamethasone used as induction chemotherapy prior to autologous transplantation.

Condition Intervention Phase
Multiple Myeloma Drug: Dexamethasone Drug: velcade Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Open-Label Phase II Study of Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by Nantes University Hospital:

Primary Outcome Measures:
  • Complete remission after 4 cycles:
  • disappearance of serum and/or urine M-component (confirmed by immunofixation)
  • < 5% plasma cells in the bone marrow resolution of all extra-osseous plasmacytomas
  • no evidence of bone progression

Estimated Enrollment: 50
Study Start Date: August 2003

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diagnosis of MM according to the SWOG criteria (annex 1)
  • previously untreated (localized radiotherapy is allowed)
  • symptomatic MM stage II or III according to Durie-Salmon staging system (annex 2) or stage I with one symptomatic osteolytic lesion
  • with measurable levels of paraprotein in the serum (> 1g/dl) or in the urine (> 0.2g/24h)
  • age < 75 years
  • able to understand and to given an informed consent
  • male, female without childbearing potential or negative urine pregnancy test within 72 hours prior to beginning the treatment. Women of childbearing potential must be following adequate contraceptive measures.
  • no active systemic infection. In the presence of any active systemic infection, adequate broad-spectrum or organism-specific antibiotic coverage must be administered. Patients must be a febrile with stable vital signs while receiving antibiotics for at least 48 hours prior to beginning the treatment with Velcade plus dexamethasone.

Exclusion Criteria:

  • life expectancy < 2 months
  • ECOG performance status > 2 (annex 3)
  • proven amyloidosis
  • positive HIV serology
  • antecedents of severe psychiatric disease
  • severe diabetes contraindicating the use of high-dose corticoïds
  • > NCI grade 2 peripheral neuropathy (Annex IV)
  • serum biochemical values as follow

    • creatinin level > 200mmol/l
    • bilirubin, transaminases or gGT > 3 the upper normal limit
  • use of any experimental drugs within 30 days of baseline
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00337506

Nantes, France, 44093
Sponsors and Collaborators
Nantes University Hospital
Principal Investigator: Jean-Luc HAROUSSEAU, MD NANTES UH
  More Information Identifier: NCT00337506     History of Changes
Other Study ID Numbers: BRD 03/6-E
Study First Received: June 14, 2006
Last Updated: June 15, 2006

Keywords provided by Nantes University Hospital:
the efficacy and safety of Velcade plus dexamethasone
Multiple Myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors processed this record on August 21, 2017